ThromboGenics NV (Euronext: THR) suffered a share price fall of just over 30% following announcement of the company’s 6-monthly US sales data on the recently launched “Jetrea” mircoplasmin treatment for vitreomacular adhesion. In a business update webcast and press release the company reported that US sales of Jetrea at the end of June 2013 amounted to EUR12.5 million ($US 16.6 million) equating to approximately 6% of the patients with moderate to severe symptomatic VMA in the US. The company is understood to be awaiting a permanent re-imbursement “J-code”, expected January 1, 2014, which the company anticipates should assist in automated claims adjudication thereby facilitating re-imbursement of physicians in a more expedient manner. Commenting on the business sales data the company stated that, “true innovation takes time to find its way to the market and requires further medical education to ensure this novel product delivers its full commercial potential”. ThromboGenics is understood to have a reimbursement support team in place to aid US physicians gain reimbursement for the drug and to assist qualified patients with potential co-pay burdens.